正在加载视频...

视频加载失败

返回首页

🚨IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION Based on Dr. William Makis MD's commonly shared dosing framework Thousands of people reference this ivermectin dosing chart. Below is a simplified breakdown organized by body weight (mg/kg per day). 📌LOW DOSE ≤ 0.5 mg/kg/day Best For: • Cancers in remission...

genixmeds's profile picture

GENIX MEDS

18,276 subscribers

31,182 次观看 • 2 个月前 •via X (Twitter)

LIVE

Anya Rossi• Live Now

Private livecam show

0 条评论

暂无评论

原始帖子的评论将显示在这里

相关视频

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information. Follow for more .
1:00

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information. Follow for more .

mcgill_medicines

103,860 次观看 • 1 个月前

🚨 DR. WILLIAM MAKIS’ IVERMECTIN DOSING GUIDE FOR CANCER & PREVENTION IS SPREADING FAST ONLINE Thousands are now discussing Dr. William Makis MD’s categorized Ivermectin dosing approach based on body weight (mg/kg/day) and cancer severity. Here’s the breakdown people keep sharing: LOW DOSE: ≤ 0.5 mg/kg/day Often discussed for: • Remission support • Prevention strategies • Strong family cancer history ⚠️ Reports shared online describe minimal long term side effects at lower ranges. Access them via PharmacyinUSA MEDIUM DOSE: 1.0 mg/kg/day Most commonly discussed for: • Breast cancer • Lung cancer • Colon cancer • Pancreatic cancer • Renal cancers ⚠️ Supporters claim this is the “standard starting range” used in many repurposed drug discussions. HIGH DOSE: 2.0 mg/kg/day Typically discussed for: • Aggressive cancers • Leukemia • Pancreatic cancer • Brain cancers ⚠️ Some anecdotal reports mention temporary visual side effects at higher dosing ranges. VERY HIGH DOSE: ≥ 2.5 mg/kg/day Usually discussed only for: • Advanced metastatic disease • Late stage aggressive cancers ⚠️ High dose use remains highly controversial and experimental. Quick weight example for a 60 kg (132 lb) adult: • Low: 30 mg/day • Medium: 60 mg/day • High: 120 mg/day • Very High: 150+ mg/day Why this conversation keeps exploding online: ✅ Ivermectin has decades of human use worldwide ✅ Growing interest in repurposed cancer drugs ✅ Observational and preclinical research continues expanding ✅ Patients are increasingly sharing personal experiences publicly. (Jase Medical) Still, millions are now asking why inexpensive repurposed drugs are generating so much public interest while receiving so little mainstream discussion. **The chart has been upscaled for better visibility** #Ivermectin #Fenbendazole #Mebendazole
5:52

🚨 DR. WILLIAM MAKIS’ IVERMECTIN DOSING GUIDE FOR CANCER & PREVENTION IS SPREADING FAST ONLINE Thousands are now discussing Dr. William Makis MD’s categorized Ivermectin dosing approach based on body weight (mg/kg/day) and cancer severity. Here’s the breakdown people keep sharing: LOW DOSE: ≤ 0.5 mg/kg/day Often discussed for: • Remission support • Prevention strategies • Strong family cancer history ⚠️ Reports shared online describe minimal long term side effects at lower ranges. Access them via PharmacyinUSA MEDIUM DOSE: 1.0 mg/kg/day Most commonly discussed for: • Breast cancer • Lung cancer • Colon cancer • Pancreatic cancer • Renal cancers ⚠️ Supporters claim this is the “standard starting range” used in many repurposed drug discussions. HIGH DOSE: 2.0 mg/kg/day Typically discussed for: • Aggressive cancers • Leukemia • Pancreatic cancer • Brain cancers ⚠️ Some anecdotal reports mention temporary visual side effects at higher dosing ranges. VERY HIGH DOSE: ≥ 2.5 mg/kg/day Usually discussed only for: • Advanced metastatic disease • Late stage aggressive cancers ⚠️ High dose use remains highly controversial and experimental. Quick weight example for a 60 kg (132 lb) adult: • Low: 30 mg/day • Medium: 60 mg/day • High: 120 mg/day • Very High: 150+ mg/day Why this conversation keeps exploding online: ✅ Ivermectin has decades of human use worldwide ✅ Growing interest in repurposed cancer drugs ✅ Observational and preclinical research continues expanding ✅ Patients are increasingly sharing personal experiences publicly. (Jase Medical) Still, millions are now asking why inexpensive repurposed drugs are generating so much public interest while receiving so little mainstream discussion. **The chart has been upscaled for better visibility** #Ivermectin #Fenbendazole #Mebendazole

PharmacyinUSA

91,070 次观看 • 3 个月前

22 Year Old With Stage 4 Turbo Cancer Post Covid "Vax" Has Major Improvement From Ivermectin and Fenbendazole‼️ Dr. William Makis, a Canadian Oncologist, shares another success story of Ivermectin overcoming stage 4 turbo cancer in a 22 year old by taking 18 mg Ivermectin tablets daily for 19 days‼️ "Another IVERMECTIN + FENBENDAZOLE success story in Alberta where AHS Cancer Care has FAILED‼️ Turbo Cancer (Stage 4 Renal Carcinoma). "There is tremendous amount of Evidence that high dose Ivermectin is extremely effective in Treating many types of Cancers"‼️🙏👇 Credit 👉Dr. Makis💫👇👇 Full Podcast🔗👇👇
0:46

22 Year Old With Stage 4 Turbo Cancer Post Covid "Vax" Has Major Improvement From Ivermectin and Fenbendazole‼️ Dr. William Makis, a Canadian Oncologist, shares another success story of Ivermectin overcoming stage 4 turbo cancer in a 22 year old by taking 18 mg Ivermectin tablets daily for 19 days‼️ "Another IVERMECTIN + FENBENDAZOLE success story in Alberta where AHS Cancer Care has FAILED‼️ Turbo Cancer (Stage 4 Renal Carcinoma). "There is tremendous amount of Evidence that high dose Ivermectin is extremely effective in Treating many types of Cancers"‼️🙏👇 Credit 👉Dr. Makis💫👇👇 Full Podcast🔗👇👇

Sophia Dahl

130,241 次观看 • 2 年前

🚨 DR. WILLIAM MAKIS REVEALED THE IVERMECTIN DOSING STRATEGY HE'S USING IN CANCER PATIENTS. HERE'S WHAT HE'S SEEING. In a recent discussion, Dr. William Makis was asked a question many cancer patients are now researching: 📌 How does he use Ivermectin in cancer protocols? His answer surprised a lot of people. For most intermediate to high-grade cancers, Dr. Makis said his typical starting dose is: 💊 1 mg/kg per day For a 60 kg (132 lb) person, that's approximately: 📊 60mg daily According to him, that's roughly 5 times higher than the dose commonly used for parasitic infections. For lower-grade cancers, he often starts lower: 💊 0.5 mg/kg per day Examples discussed included: • Chronic Lymphocytic Leukemia (CLL) • Multiple Myeloma For a 60 kg person, that would be about: 📊 30mg daily And unlike many protocols circulating online, he noted that the dosing is typically: 📅 7 days per week But the dosage wasn't the part that got my attention. The timeline was. According to Dr. Makis, some patients may begin seeing changes in cancer markers within: ⏳ 3 to 4 weeks He specifically mentioned markers such as: 📉 PSA 📉 CEA 📉 CA-125 📉 Other cancer-related markers He explained that these markers can sometimes provide an early indication that something is changing before tumors physically shrink. Then come the scans. According to his experience: 📊 PET scans may begin showing reduced cancer activity within about a month. 📊 Physical tumor shrinkage often becomes visible after roughly 2 to 3 months on PET-CT, CT, or MRI imaging. That's why he generally recommends giving a protocol: ⏳ A full 3 months Before evaluating whether a meaningful response is occurring. But perhaps the most surprising statement came near the end. Dr. Makis said the best results he has personally seen were not necessarily from Ivermectin alone. According to him, some of the most dramatic responses occurred when patients combined: 💊 Ivermectin PLUS 💊 Chemotherapy That observation is likely to spark debate from every side of the conversation. Whether you agree with his conclusions or not, one thing is clear: More patients are reading studies. More doctors are discussing repurposed medicines. And more people are asking questions that weren't being asked a few years ago. That's why conversations around Ivermectin continue to grow across cancer communities worldwide. 🌐 Looking for Ivermectin, Fenbendazole, or Mebendazole? Explore RXMEDS.STORE. #Ivermectin #WilliamMakis #CancerResearch #CancerProtocol #RepurposedDrugs
3:34

🚨 DR. WILLIAM MAKIS REVEALED THE IVERMECTIN DOSING STRATEGY HE'S USING IN CANCER PATIENTS. HERE'S WHAT HE'S SEEING. In a recent discussion, Dr. William Makis was asked a question many cancer patients are now researching: 📌 How does he use Ivermectin in cancer protocols? His answer surprised a lot of people. For most intermediate to high-grade cancers, Dr. Makis said his typical starting dose is: 💊 1 mg/kg per day For a 60 kg (132 lb) person, that's approximately: 📊 60mg daily According to him, that's roughly 5 times higher than the dose commonly used for parasitic infections. For lower-grade cancers, he often starts lower: 💊 0.5 mg/kg per day Examples discussed included: • Chronic Lymphocytic Leukemia (CLL) • Multiple Myeloma For a 60 kg person, that would be about: 📊 30mg daily And unlike many protocols circulating online, he noted that the dosing is typically: 📅 7 days per week But the dosage wasn't the part that got my attention. The timeline was. According to Dr. Makis, some patients may begin seeing changes in cancer markers within: ⏳ 3 to 4 weeks He specifically mentioned markers such as: 📉 PSA 📉 CEA 📉 CA-125 📉 Other cancer-related markers He explained that these markers can sometimes provide an early indication that something is changing before tumors physically shrink. Then come the scans. According to his experience: 📊 PET scans may begin showing reduced cancer activity within about a month. 📊 Physical tumor shrinkage often becomes visible after roughly 2 to 3 months on PET-CT, CT, or MRI imaging. That's why he generally recommends giving a protocol: ⏳ A full 3 months Before evaluating whether a meaningful response is occurring. But perhaps the most surprising statement came near the end. Dr. Makis said the best results he has personally seen were not necessarily from Ivermectin alone. According to him, some of the most dramatic responses occurred when patients combined: 💊 Ivermectin PLUS 💊 Chemotherapy That observation is likely to spark debate from every side of the conversation. Whether you agree with his conclusions or not, one thing is clear: More patients are reading studies. More doctors are discussing repurposed medicines. And more people are asking questions that weren't being asked a few years ago. That's why conversations around Ivermectin continue to grow across cancer communities worldwide. 🌐 Looking for Ivermectin, Fenbendazole, or Mebendazole? Explore RXMEDS.STORE. #Ivermectin #WilliamMakis #CancerResearch #CancerProtocol #RepurposedDrugs

RXMEDS.STORE

37,349 次观看 • 2 个月前

🚨 WHY IVERMECTIN DOSING ISN'T ONE SIZE FITS ALL. THIS PHYSICIAN EXPLAINS THE DIFFERENCE. A physician starts with a point that many people overlook: Ivermectin dosing is weight based. So before discussing any amount, she starts with body weight. 📌 Her conversion: Weight in pounds ÷ 2.2 = kilograms Her example: 130 lb ÷ 2.2 ≈ 59 kg But that's only the starting point. She then explains that the amount she discusses changes depending on what Ivermectin is being used for. 💊 PREVENTION 0.2 mg/kg twice a week 💊 PARASITE CLEANSE 0.3 mg/kg She says she then follows the protocol associated with her parasite cleanse. 💊 COVID, FLU OR RSV She describes a range of: 0.4 to 0.6 mg/kg She also explains that she may round the calculated amount upward to an even 5 mg increment. Then comes the most variable category. 💊 CANCER She says the amount can depend on: • Cancer type • Cancer stage • Disease progression • How aggressive the approach is She says she may go as high as: 📈 1 mg/kg or higher Then she gives the principle behind her entire explanation: "It just depends on what you're doing it for." And the lowest amount she says she would use? 📌 0.2 mg/kg But the bigger takeaway from this discussion is simple: Ivermectin dosing depends on what it is being used for, not just body weight. And simply converting pounds to kilograms and applying a number isn't enough to determine an appropriate treatment plan. Indication, formulation, other medications, medical history, and safety all matter. Ivermectin has a long history of human use, but higher doses can increase the risk of adverse effects. The FDA also distinguishes human ivermectin products from veterinary formulations, which are not substitutes for medicines intended for people. And when the indication is experimental, particularly cancer, the dosing question is something clinical research still needs to answer. 📌 Save this post if you're researching Ivermectin dosing and want to understand why there isn't one universal number. 🔄 Repost it so others researching Ivermectin can see the discussion. 💊 Exploring Ivermectin? See why thousands of customers worldwide choose RXMEDS.STORE for pharmaceutical grade Ivermectin. #Ivermectin #IvermectinDosage #IvermectinResearch #RepurposedDrugs #MedicalResearch
1:42

🚨 WHY IVERMECTIN DOSING ISN'T ONE SIZE FITS ALL. THIS PHYSICIAN EXPLAINS THE DIFFERENCE. A physician starts with a point that many people overlook: Ivermectin dosing is weight based. So before discussing any amount, she starts with body weight. 📌 Her conversion: Weight in pounds ÷ 2.2 = kilograms Her example: 130 lb ÷ 2.2 ≈ 59 kg But that's only the starting point. She then explains that the amount she discusses changes depending on what Ivermectin is being used for. 💊 PREVENTION 0.2 mg/kg twice a week 💊 PARASITE CLEANSE 0.3 mg/kg She says she then follows the protocol associated with her parasite cleanse. 💊 COVID, FLU OR RSV She describes a range of: 0.4 to 0.6 mg/kg She also explains that she may round the calculated amount upward to an even 5 mg increment. Then comes the most variable category. 💊 CANCER She says the amount can depend on: • Cancer type • Cancer stage • Disease progression • How aggressive the approach is She says she may go as high as: 📈 1 mg/kg or higher Then she gives the principle behind her entire explanation: "It just depends on what you're doing it for." And the lowest amount she says she would use? 📌 0.2 mg/kg But the bigger takeaway from this discussion is simple: Ivermectin dosing depends on what it is being used for, not just body weight. And simply converting pounds to kilograms and applying a number isn't enough to determine an appropriate treatment plan. Indication, formulation, other medications, medical history, and safety all matter. Ivermectin has a long history of human use, but higher doses can increase the risk of adverse effects. The FDA also distinguishes human ivermectin products from veterinary formulations, which are not substitutes for medicines intended for people. And when the indication is experimental, particularly cancer, the dosing question is something clinical research still needs to answer. 📌 Save this post if you're researching Ivermectin dosing and want to understand why there isn't one universal number. 🔄 Repost it so others researching Ivermectin can see the discussion. 💊 Exploring Ivermectin? See why thousands of customers worldwide choose RXMEDS.STORE for pharmaceutical grade Ivermectin. #Ivermectin #IvermectinDosage #IvermectinResearch #RepurposedDrugs #MedicalResearch

RXMEDS.STORE

31,658 次观看 • 9 天前

🚨 SHOCKING BOMBSHELL: They’ve been hiding this from you. Dr. Peter McCullough just exposed it in this video: A new real-world study of 197 cancer patients treated with low-dose Ivermectin (25 mg) + Mebendazole (250 mg). After just 6 months: 84.4% had clinical benefit 48.4% had tumor reduction or no detectable disease 86.9% completed treatment with only mild side effects Patients got scans every 3 months. Dr. McCullough breaks it down: tiny doses, massive results, and almost no downside. This is what the cancer industry and Big Pharma fear most — cheap, repurposed drugs actually working while they push trillion-dollar chemo and endless “treatments.” Cancer isn’t being cured because it’s too profitable.
1:33

🚨 SHOCKING BOMBSHELL: They’ve been hiding this from you. Dr. Peter McCullough just exposed it in this video: A new real-world study of 197 cancer patients treated with low-dose Ivermectin (25 mg) + Mebendazole (250 mg). After just 6 months: 84.4% had clinical benefit 48.4% had tumor reduction or no detectable disease 86.9% completed treatment with only mild side effects Patients got scans every 3 months. Dr. McCullough breaks it down: tiny doses, massive results, and almost no downside. This is what the cancer industry and Big Pharma fear most — cheap, repurposed drugs actually working while they push trillion-dollar chemo and endless “treatments.” Cancer isn’t being cured because it’s too profitable.

Dr. Dawn Michael

116,089 次观看 • 1 个月前

Ivermectin is often recognized–2nd to penicillin–for having the greatest impact on human health. Its discovery even won the Nobel Prize. But the propagandists told you it was a “dangerous horse dewormer.” Well, it now turns out that ivermectin has multiple anti-cancer effects. “There are at least nine perfectly defined cancer targets affected by ivermectin,” oncologist Dr. Alfonso Dueñas-González, told The Epoch Times. The news outlet reported: "It [ivermectin] has a broad impact on the immune system, increasing immune offense against cancers." "It also inhibits cancer cell cycles, helping prevent the formation of new cancer cells. The drug promotes the killing of cancer cells by inducing mitochondrial stress and prevents cancer survival by preventing new blood vessels, which transport energy and fuel to cancers, from forming near cancer cells." Dr. Kathleen Ruddy, a cancer surgeon, observed a resounding improvement in three patients under her consultation after they started using ivermectin with additional therapies. One patient, facing terminal stage 4 prostate cancer and given only three weeks to live after all treatments failed, began using ivermectin. Remarkably, within two months, his indicators of prostate cancer plummeted, and by six months, his cancer had significantly receded. Less than a year later, he was energetically dancing for four hours, three nights a week. This miraculous recovery was not isolated, as two more patients experienced similar outcomes. Dr. Ruddy, with over 30 years in cancer surgery, reflected on these cases, saying, “I’ve been a cancer surgeon for over 30 years. I’ve never seen anything like this in one patient—let alone three in a row.” Read the full report in the comment below:
3:07

Ivermectin is often recognized–2nd to penicillin–for having the greatest impact on human health. Its discovery even won the Nobel Prize. But the propagandists told you it was a “dangerous horse dewormer.” Well, it now turns out that ivermectin has multiple anti-cancer effects. “There are at least nine perfectly defined cancer targets affected by ivermectin,” oncologist Dr. Alfonso Dueñas-González, told The Epoch Times. The news outlet reported: "It [ivermectin] has a broad impact on the immune system, increasing immune offense against cancers." "It also inhibits cancer cell cycles, helping prevent the formation of new cancer cells. The drug promotes the killing of cancer cells by inducing mitochondrial stress and prevents cancer survival by preventing new blood vessels, which transport energy and fuel to cancers, from forming near cancer cells." Dr. Kathleen Ruddy, a cancer surgeon, observed a resounding improvement in three patients under her consultation after they started using ivermectin with additional therapies. One patient, facing terminal stage 4 prostate cancer and given only three weeks to live after all treatments failed, began using ivermectin. Remarkably, within two months, his indicators of prostate cancer plummeted, and by six months, his cancer had significantly receded. Less than a year later, he was energetically dancing for four hours, three nights a week. This miraculous recovery was not isolated, as two more patients experienced similar outcomes. Dr. Ruddy, with over 30 years in cancer surgery, reflected on these cases, saying, “I’ve been a cancer surgeon for over 30 years. I’ve never seen anything like this in one patient—let alone three in a row.” Read the full report in the comment below:

The Vigilant Fox 🦊

1,192,348 次观看 • 2 年前

100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Cercek explained that it essentially unlocks the body’s ability to heal itself.
3:28

100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Cercek explained that it essentially unlocks the body’s ability to heal itself.

The Vigilant Fox 🦊

1,600,484 次观看 • 2 年前

100% Cancer Remission Achieved in ALL Patients of Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Andrea Cercek explained that it essentially unlocks the body’s ability to heal itself.
3:28

100% Cancer Remission Achieved in ALL Patients of Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Andrea Cercek explained that it essentially unlocks the body’s ability to heal itself.

The Vigilant Fox 🦊

2,527,788 次观看 • 2 年前

🚨 76-YEAR-OLD WITH GLEASON 7 PROSTATE CANCER TAKES IVERMECTIN. 12 WEEKS LATER, PET SCAN SHOWS NOTHING. A doctor shared the story of a 76-year-old veteran who had been diagnosed with Gleason 7 prostate cancer. According to the doctor, the patient began taking 12 mg of Ivermectin daily. After eight weeks, he continued with follow-up testing. At around 12 weeks, he underwent a specialized PET scan looking for abnormalities associated with the prostate. The doctor says the scan could no longer find the cancerous abnormalities. There was another change too. His PSA, which had been 12.6 when the cancer was initially diagnosed, had dropped to 5.3. That is a significant change in the numbers the doctor shared. The story raises an obvious question about the potential role of Ivermectin in prostate cancer, particularly given the growing interest in repurposing older medicines for oncology. Ivermectin is already well established as an antiparasitic medicine, while research into its potential anticancer effects continues to explore mechanisms involving cancer cell growth, survival and signaling. Could Ivermectin deserve a closer look in prostate cancer research?
0:48

🚨 76-YEAR-OLD WITH GLEASON 7 PROSTATE CANCER TAKES IVERMECTIN. 12 WEEKS LATER, PET SCAN SHOWS NOTHING. A doctor shared the story of a 76-year-old veteran who had been diagnosed with Gleason 7 prostate cancer. According to the doctor, the patient began taking 12 mg of Ivermectin daily. After eight weeks, he continued with follow-up testing. At around 12 weeks, he underwent a specialized PET scan looking for abnormalities associated with the prostate. The doctor says the scan could no longer find the cancerous abnormalities. There was another change too. His PSA, which had been 12.6 when the cancer was initially diagnosed, had dropped to 5.3. That is a significant change in the numbers the doctor shared. The story raises an obvious question about the potential role of Ivermectin in prostate cancer, particularly given the growing interest in repurposing older medicines for oncology. Ivermectin is already well established as an antiparasitic medicine, while research into its potential anticancer effects continues to explore mechanisms involving cancer cell growth, survival and signaling. Could Ivermectin deserve a closer look in prostate cancer research?

Joe Tippens

38,802 次观看 • 12 天前

Ivermectin and Mebendazole in Cancer Patients The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Overall, it is estimated that annual costs of standard chemotherapies average $111,000 per year. Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol. Methods: Prospective observational cohort of 197 cancer patients, who were prescribed ivermectin and mebendazole off-label through telemedicine (platform by licensed U.S. healthcare providers) Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. Data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) Results: Mean age of 67 years, (52.3% male, 47.7% female). Cancer types included Prostate 27.9% Breast 18.3% Lung 8.6% Colon 5.1% Urologic 4.6% Pancreatic 3.0% Liver 2.5% Gynaecologic 2.5% Hematologic 2.5% Median duration since initial diagnosis, 1.2 years 37.1% experiencing active disease progression. 6-month follow-up Medication adherence, 86.9% Full initial 90-capsule ivermectin-mebendazole prescription. The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Notably, 48.4% of cohort, strongest positive outcomes: Regression, 15.6% No current evidence of disease (NED), 32.8% Disease stability, 36.1% Disease progression, 15.6% No significant dose-response association was observed for cancer outcomes (p = 0.91), without a clear dose-response gradient for efficacy. Side effects Mild side effects (primarily gastrointestinal), 25.4% (93.6% of those affected continued treatment through minor dose adjustments) Concurrent conventional therapies Chemotherapy, 27.9% Radiation therapy, 21.3% Surgery, 19.7% Adjunctive interventions such as supplement use, 49.2% Dietary modification, 37.7% Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumours regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials Validate these observations and further define optimal dosing strategies. Mechanism (pharmacodynamics) Ivermectin and mebendazole are antiparasitic agents, demonstrated highly promising anti-cancer activity. Ivermectin Shown to exert over 14 distinct anti-cancer mechanisms across more than 12 cancer types, inhibiting cancer cell proliferation, metastasis, angiogenesis, mitochondrial function. Has demonstrated excellent safety in cancer patients (including those actively undergoing chemotherapy) Ivermectin and mebendazole selectively target cancer stem cells Mebendazole Microtubule disruption, leading to effective cell cycle arrest Potent induction of apoptosis Significant inhibition of tumour growth Inhibition of angiogenesis Disruption of glucose uptake When used together Target non-overlapping pathways, resulting in synergistic tumour regression, cancer stem cell depletion, and reversal of multidrug resistance in multiple in vitro and in vivo models Biodistribution, ivermectin and mebendazole document excellent tissue penetration
24:40

Ivermectin and Mebendazole in Cancer Patients The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Overall, it is estimated that annual costs of standard chemotherapies average $111,000 per year. Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol. Methods: Prospective observational cohort of 197 cancer patients, who were prescribed ivermectin and mebendazole off-label through telemedicine (platform by licensed U.S. healthcare providers) Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. Data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) Results: Mean age of 67 years, (52.3% male, 47.7% female). Cancer types included Prostate 27.9% Breast 18.3% Lung 8.6% Colon 5.1% Urologic 4.6% Pancreatic 3.0% Liver 2.5% Gynaecologic 2.5% Hematologic 2.5% Median duration since initial diagnosis, 1.2 years 37.1% experiencing active disease progression. 6-month follow-up Medication adherence, 86.9% Full initial 90-capsule ivermectin-mebendazole prescription. The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Notably, 48.4% of cohort, strongest positive outcomes: Regression, 15.6% No current evidence of disease (NED), 32.8% Disease stability, 36.1% Disease progression, 15.6% No significant dose-response association was observed for cancer outcomes (p = 0.91), without a clear dose-response gradient for efficacy. Side effects Mild side effects (primarily gastrointestinal), 25.4% (93.6% of those affected continued treatment through minor dose adjustments) Concurrent conventional therapies Chemotherapy, 27.9% Radiation therapy, 21.3% Surgery, 19.7% Adjunctive interventions such as supplement use, 49.2% Dietary modification, 37.7% Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumours regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials Validate these observations and further define optimal dosing strategies. Mechanism (pharmacodynamics) Ivermectin and mebendazole are antiparasitic agents, demonstrated highly promising anti-cancer activity. Ivermectin Shown to exert over 14 distinct anti-cancer mechanisms across more than 12 cancer types, inhibiting cancer cell proliferation, metastasis, angiogenesis, mitochondrial function. Has demonstrated excellent safety in cancer patients (including those actively undergoing chemotherapy) Ivermectin and mebendazole selectively target cancer stem cells Mebendazole Microtubule disruption, leading to effective cell cycle arrest Potent induction of apoptosis Significant inhibition of tumour growth Inhibition of angiogenesis Disruption of glucose uptake When used together Target non-overlapping pathways, resulting in synergistic tumour regression, cancer stem cell depletion, and reversal of multidrug resistance in multiple in vitro and in vivo models Biodistribution, ivermectin and mebendazole document excellent tissue penetration

Dr. Zakaria MD

10,766 次观看 • 2 个月前

Top Doctor Exposes the Sobering Truth About Chemotherapy Dr. Paul Marik has shed light on the grim reality of chemotherapy’s ineffectiveness in treating cancer. He revealed that only “about 5% of all cancers are actually curable with chemotherapy.” For the other 95%, chemo is “palliative at best,” he said. The truly sobering detail that Dr. Marik mentioned was that despite advancements in chemotherapy, immunotherapy, and surgical treatments over the past 30 years, the overall life expectancy of a cancer patient has been extended by a measly 3.9 months. Dr. Marik urges cancer patients to ask their oncologists a vital question: “Is this [chemotherapy] going to cure my cancer, or is it just going to palliate and extend my life a month or two with terrible side effects?” “Hopefully, they’ll be honest,” he added.
4:26

Top Doctor Exposes the Sobering Truth About Chemotherapy Dr. Paul Marik has shed light on the grim reality of chemotherapy’s ineffectiveness in treating cancer. He revealed that only “about 5% of all cancers are actually curable with chemotherapy.” For the other 95%, chemo is “palliative at best,” he said. The truly sobering detail that Dr. Marik mentioned was that despite advancements in chemotherapy, immunotherapy, and surgical treatments over the past 30 years, the overall life expectancy of a cancer patient has been extended by a measly 3.9 months. Dr. Marik urges cancer patients to ask their oncologists a vital question: “Is this [chemotherapy] going to cure my cancer, or is it just going to palliate and extend my life a month or two with terrible side effects?” “Hopefully, they’ll be honest,” he added.

Vigilant Fox 🦊

464,904 次观看 • 2 年前

Top Doctor Exposes the Sobering Truth About Chemotherapy Dr. Paul Marik has shed light on the grim reality of chemotherapy’s ineffectiveness in treating cancer. He revealed that only “about 5% of all cancers are actually curable with chemotherapy.” For the other 95%, chemo is “palliative at best,” he said. The truly sobering detail that Dr. Marik mentioned was that despite advancements in chemotherapy, immunotherapy, and surgical treatments over the past 30 years, the overall life expectancy of a cancer patient has been extended by a measly 3.9 months. Dr. Marik urges cancer patients to ask their oncologists a vital question: “Is this [chemotherapy] going to cure my cancer, or is it just going to palliate and extend my life a month or two with terrible side effects?” “Hopefully, they’ll be honest,” he added.
4:26

Top Doctor Exposes the Sobering Truth About Chemotherapy Dr. Paul Marik has shed light on the grim reality of chemotherapy’s ineffectiveness in treating cancer. He revealed that only “about 5% of all cancers are actually curable with chemotherapy.” For the other 95%, chemo is “palliative at best,” he said. The truly sobering detail that Dr. Marik mentioned was that despite advancements in chemotherapy, immunotherapy, and surgical treatments over the past 30 years, the overall life expectancy of a cancer patient has been extended by a measly 3.9 months. Dr. Marik urges cancer patients to ask their oncologists a vital question: “Is this [chemotherapy] going to cure my cancer, or is it just going to palliate and extend my life a month or two with terrible side effects?” “Hopefully, they’ll be honest,” he added.

Barbara Oneill

109,921 次观看 • 2 年前

🚨 #BREAKING: New PubMed peer reviewed study shows 84% of cancer patients taking ivermectin + mebendazole disappeared, shrunk, or stopped spreading after several months 🔻 The Study and Important Caveats: Researchers followed 197 cancer patients who took a combination of ivermectin and mebendazole (off-label, through a telemedicine service). After 6 months, 122 of them filled out a follow-up survey. Among those 122 people: 84% said their cancer had either completely disappeared, shrunk, or stopped spreading. About 33% reported “no evidence of disease” About 16% reported the tumors got smaller About 36% said the cancer stayed the same (stable) 16% said it got worse Side effects were mostly mild (mainly stomach issues) and most people kept taking the medicine. 🔻 Important caveats: • The results come only from patient surveys — no doctors independently checked scans or medical records. • There was no control group to compare against. • Many patients were also getting regular cancer treatments (chemo, radiation, surgery, etc.) at the same time. • About 38% of the original group didn’t finish the survey. • The journal later issued an official “Expression of Concern” and started an audit because of questions about the data. • The authors say these findings are just a starting point and that proper clinical trials are still needed. 🔻What kinds of cancer were included? Most common Prostate: 55 patients (27.9%) Breast: 36 patients (18.3%) Lung: 17 patients (8.6%) Colon: 10 patients (5.1%) Liver: 5 patients (2.5%) Other cancers (74 patients / 37.6%) Urologic (bladder & kidney): 9 Pancreatic & bile duct: 6 Hematologic (lymphoma): 5 Head, neck & oral: 5 Gynecologic (ovarian & uterine): 5 Thyroid: 4 Brain & neurological: 3 Multiple myeloma: 3 Melanoma (skin & ocular): 3 Sarcoma: 2 Miscellaneous/unspecified: 29 🔻Final Note: The study does not show which cancers benefited the most. All the results (including the 84% figure) are reported only as overall numbers. Clip Study
0:33

🚨 #BREAKING: New PubMed peer reviewed study shows 84% of cancer patients taking ivermectin + mebendazole disappeared, shrunk, or stopped spreading after several months 🔻 The Study and Important Caveats: Researchers followed 197 cancer patients who took a combination of ivermectin and mebendazole (off-label, through a telemedicine service). After 6 months, 122 of them filled out a follow-up survey. Among those 122 people: 84% said their cancer had either completely disappeared, shrunk, or stopped spreading. About 33% reported “no evidence of disease” About 16% reported the tumors got smaller About 36% said the cancer stayed the same (stable) 16% said it got worse Side effects were mostly mild (mainly stomach issues) and most people kept taking the medicine. 🔻 Important caveats: • The results come only from patient surveys — no doctors independently checked scans or medical records. • There was no control group to compare against. • Many patients were also getting regular cancer treatments (chemo, radiation, surgery, etc.) at the same time. • About 38% of the original group didn’t finish the survey. • The journal later issued an official “Expression of Concern” and started an audit because of questions about the data. • The authors say these findings are just a starting point and that proper clinical trials are still needed. 🔻What kinds of cancer were included? Most common Prostate: 55 patients (27.9%) Breast: 36 patients (18.3%) Lung: 17 patients (8.6%) Colon: 10 patients (5.1%) Liver: 5 patients (2.5%) Other cancers (74 patients / 37.6%) Urologic (bladder & kidney): 9 Pancreatic & bile duct: 6 Hematologic (lymphoma): 5 Head, neck & oral: 5 Gynecologic (ovarian & uterine): 5 Thyroid: 4 Brain & neurological: 3 Multiple myeloma: 3 Melanoma (skin & ocular): 3 Sarcoma: 2 Miscellaneous/unspecified: 29 🔻Final Note: The study does not show which cancers benefited the most. All the results (including the 84% figure) are reported only as overall numbers. Clip Study

MJTruthUltra

29,659 次观看 • 10 天前

This is phenomenal! Histotripsy is the non-invasive destruction of cancer tumors using focused ultrasound waves - no surgery, chemo or radiation. It liquifies targeted tissue with no reported side effects. Now approved for use in liver cancer. HistoSonics CEO Mike Blu - ‘I think we’ll look back and there will be a day where we cannot believe we used to do invasive surgical procedures.’ He continues to gather data to prove this point and gain further FDA approvals. To date thousands have successfully had tumors destroyed. What a game changer.
3:30

This is phenomenal! Histotripsy is the non-invasive destruction of cancer tumors using focused ultrasound waves - no surgery, chemo or radiation. It liquifies targeted tissue with no reported side effects. Now approved for use in liver cancer. HistoSonics CEO Mike Blu - ‘I think we’ll look back and there will be a day where we cannot believe we used to do invasive surgical procedures.’ He continues to gather data to prove this point and gain further FDA approvals. To date thousands have successfully had tumors destroyed. What a game changer.

Kat A 🌸

31,266 次观看 • 6 个月前

7 Compelling Reasons Why Ivermectin Is a ‘Powerful Drug’ for Fighting Cancer Ivermectin is often recognized–2nd to penicillin–for having the greatest impact on human health. Its discovery even won the Nobel Prize. It is safer than Tylenol and brought river blindness to the brink of extinction, but the propagandists told you it was a “dangerous horse dewormer.” Well, it now turns out that ivermectin is not only an effective treatment for COVID-19, but it could also be a “powerful drug” for fighting cancer. Here are 7 reasons why. 1. Multiple Anti-Cancer Effects: Ivermectin impacts at least nine well-defined cancer targets, according to Dr. Alfonso Dueñas-González, an oncologist and senior researcher. He states, "There are at least nine perfectly defined cancer targets affected by ivermectin." 2. Enhances Effects of Chemotherapy and Radiation: Ivermectin not only targets tumor stem cells and promotes cancer cell death but also "enhances the effects of chemo and radiation therapy." This broad impact on the immune system increases the offense against cancers, making it a versatile adjunct to conventional treatments. 3. Inhibits Cancer Cell Cycles: The drug prevents the formation of new cancer cells by inhibiting cancer cell cycles and inducing mitochondrial stress, which leads to the killing of cancer cells. This mechanism is crucial for stopping the proliferation of cancerous cells. 4. Prevents Formation of New Blood Vessels Near Cancer Cells: Ivermectin prevents cancer survival by inhibiting the formation of new blood vessels that transport energy and fuel to cancers. This action starves the cancer cells, hindering their growth and spread. 5. Synergizes with Immunotherapy: Dr. Peter P. Lee, chair of immuno-oncology at the City of Hope, found that ivermectin could synergize with immune checkpoint inhibitor anti-PD1, enhancing the body's immune response to fight cancer. "What we’re learning is that ivermectin is going to be a very powerful drug in the context of really carefully developed immunotherapy combinations," he said. 6. Targets Cancer Stem Cells: Ivermectin preferentially targets cancer stem cells, which are a driver of cancer tumors and relapses. By focusing on these cells, ivermectin attacks the root of cancer's resilience and ability to recur. 7. The Curious Case of Rick Alderson: Mr. Alderson, a retired sawmill worker, “was a dead man walking” and given 6 months to live after his terminal colon cancer had metastasized and spread to his liver, where it had formed 25 distinct tumors. After starting ivermectin, Rick Alderson's carcinoembryonic antigen (CEA) levels, which are markers for tumor activity, dropped significantly from 1,498 ng/mL to 13.9 ng/mL in a matter of months. Of the 25 tumors in Mr. Alderson's liver, only three remained after his treatment with ivermectin and chemotherapy, indicating a substantial reduction in tumor burden. Mr. Alderson lived for two more years beyond his initial six-month prognosis, which his wife attributes to the use of ivermectin alongside chemotherapy.
3:43

7 Compelling Reasons Why Ivermectin Is a ‘Powerful Drug’ for Fighting Cancer Ivermectin is often recognized–2nd to penicillin–for having the greatest impact on human health. Its discovery even won the Nobel Prize. It is safer than Tylenol and brought river blindness to the brink of extinction, but the propagandists told you it was a “dangerous horse dewormer.” Well, it now turns out that ivermectin is not only an effective treatment for COVID-19, but it could also be a “powerful drug” for fighting cancer. Here are 7 reasons why. 1. Multiple Anti-Cancer Effects: Ivermectin impacts at least nine well-defined cancer targets, according to Dr. Alfonso Dueñas-González, an oncologist and senior researcher. He states, "There are at least nine perfectly defined cancer targets affected by ivermectin." 2. Enhances Effects of Chemotherapy and Radiation: Ivermectin not only targets tumor stem cells and promotes cancer cell death but also "enhances the effects of chemo and radiation therapy." This broad impact on the immune system increases the offense against cancers, making it a versatile adjunct to conventional treatments. 3. Inhibits Cancer Cell Cycles: The drug prevents the formation of new cancer cells by inhibiting cancer cell cycles and inducing mitochondrial stress, which leads to the killing of cancer cells. This mechanism is crucial for stopping the proliferation of cancerous cells. 4. Prevents Formation of New Blood Vessels Near Cancer Cells: Ivermectin prevents cancer survival by inhibiting the formation of new blood vessels that transport energy and fuel to cancers. This action starves the cancer cells, hindering their growth and spread. 5. Synergizes with Immunotherapy: Dr. Peter P. Lee, chair of immuno-oncology at the City of Hope, found that ivermectin could synergize with immune checkpoint inhibitor anti-PD1, enhancing the body's immune response to fight cancer. "What we’re learning is that ivermectin is going to be a very powerful drug in the context of really carefully developed immunotherapy combinations," he said. 6. Targets Cancer Stem Cells: Ivermectin preferentially targets cancer stem cells, which are a driver of cancer tumors and relapses. By focusing on these cells, ivermectin attacks the root of cancer's resilience and ability to recur. 7. The Curious Case of Rick Alderson: Mr. Alderson, a retired sawmill worker, “was a dead man walking” and given 6 months to live after his terminal colon cancer had metastasized and spread to his liver, where it had formed 25 distinct tumors. After starting ivermectin, Rick Alderson's carcinoembryonic antigen (CEA) levels, which are markers for tumor activity, dropped significantly from 1,498 ng/mL to 13.9 ng/mL in a matter of months. Of the 25 tumors in Mr. Alderson's liver, only three remained after his treatment with ivermectin and chemotherapy, indicating a substantial reduction in tumor burden. Mr. Alderson lived for two more years beyond his initial six-month prognosis, which his wife attributes to the use of ivermectin alongside chemotherapy.

The Vigilant Fox 🦊

532,851 次观看 • 2 年前

Oncologist Dr. William Makis: "The turbo cancers after the COVID vaccines do respond to the antiparasitics, and they respond very well... [And] why do these antiparasitics work?" Todd Callender: "Cancer's a parasite?" Makis: "That's one possibility." This clip of Dr. Makis (William Makis), a radiologist, oncologist, and cancer researcher, is taken from an interview with attorney Todd Callender posted to the VaxxCHOICE (VaxxCHOICE) Rumble channel on November 21, 2025. ---------------Partial transcription of clip---------------- Dr. Makis: "The turbo cancers after the COVID vaccines do respond to the antiparasitics and they respond very well. This is, you know, whether it's ivermectin, fenbendazole or mebendazole, these patients are responding. "Now this is very important because patients who've developed cancer after taking Covid vaccines, they don't respond usually to conventional treatments. That's one of the hallmarks of turbo cancer is they present at a very late stage. These are extremely rapidly growing tumors. They're coming in at stage four. And it's whether it's young women with breast cancer, women in their 20s, something we've never seen before, young women with, men and women with colon cancer in their 20s and 30s. "Again, we've never seen—" Callender: "Two- year-olds, I've heard of two- year-olds with colon cancer—" Dr. Makis: "—we've never seen this before. That's the incredible part. And they're not responding to conventional treatments. So, they're not responding to chemo, they're not responding to radiation therapy, immunotherapy, or if they do response, they have a very, very short response time or remission time. And then the cancer comes roaring back. "And in a lot of these tragic cases, the patient dies within six months. This is another one of the features of turbo cancer is the prognosis is extremely poor if you go the conventional route. So you need something else. Now when you're using antiparasitics, for cancer, the dose is higher than the dose you would use to treat parasites or to treat Covid. So I give just a rule of thumb for ivermectin, for example, it's about five times the dose that you would need for cancer, about 5 to 10 times the dose than if you were just treating parasites or viruses. "And to go into the— why does it work? Why do these antiparasitics work?" Callender: "Cancer's a parasite?" Dr. Makis: "Well, that's one possibility. But there's more to it than that because, out of the 400 papers that have been published, a lot of those researchers look at the mechanisms. They are trying to identify the mechanisms of how ivermectin is treating these cancers. "And you've got, for example, there was one study published a few years ago, Mexican researchers, again, you're not going to see this done in the United States, Mexico. Mexican researchers took 28 different cancer cell lines, applied ivermectin to them, and all of them responded. Now to various degrees, you had breast cancer and ovarian cancer actually responding the most to ivermectin. You had the most cancer cell killing when they were exposed to ivermectin. "But when they look at the mechanisms, they've identified a number of interesting things. For example, ivermectin shuts down and kills cancer stem cells. Now, this is important because cancer stem cells are the reason chemotherapy doesn't work. When you have stage four pancreatic cancer, stage four ovarian cancer, and you go to your oncologist, they will tell you, we will give you chemo, but we can't cure you. It's palliative chemo. It'll buy you an extra six months, an extra 12 months of life. "The reason why they say that is why the chemo is palliative, not curative. It's is because chemo cannot kill cancer stem cells, which are not rapidly dividing. Chemo will kill everything that's rapidly dividing, but cancer stem cells are not rapidly dividing. And so the chemo will kill the rapidly dividing tumor cells, and it'll leave the cancer stem cells alone, while the cancer stem cells will start rapidly dividing a year later, two years later, they're going to spread to other parts of the body. Suddenly you've got recurrence, you've got metastases. Ivermectin will shut down and kill cancer stem cells. "So imagine you, added to your chemo regimen, and now you've essentially turned what's palliative chemo or a palliative situation to potentially a curative situation. And I really do believe I've come to the point, having helped over 7,000 cancer patients in the last year, I've come to the point where I could confidently say that stage 4 pancreatic cancer is curable, stage 4 ovarian cancer is curable, stage 4 colon cancer, lung cancer. These cancers are curable. I think if you add repurposed drugs, you add antiparasitics, you can turn these into curable situations. "Now, of course, we have to prove that. We have to do the research, do the publications. But in the meantime, I say stage 4 cancer patients don't have 10 years to wait for mainstream oncology or mainstream medicine to catch up with what we're seeing already clinically, in practice."
4:27

Oncologist Dr. William Makis: "The turbo cancers after the COVID vaccines do respond to the antiparasitics, and they respond very well... [And] why do these antiparasitics work?" Todd Callender: "Cancer's a parasite?" Makis: "That's one possibility." This clip of Dr. Makis (William Makis), a radiologist, oncologist, and cancer researcher, is taken from an interview with attorney Todd Callender posted to the VaxxCHOICE (VaxxCHOICE) Rumble channel on November 21, 2025. ---------------Partial transcription of clip---------------- Dr. Makis: "The turbo cancers after the COVID vaccines do respond to the antiparasitics and they respond very well. This is, you know, whether it's ivermectin, fenbendazole or mebendazole, these patients are responding. "Now this is very important because patients who've developed cancer after taking Covid vaccines, they don't respond usually to conventional treatments. That's one of the hallmarks of turbo cancer is they present at a very late stage. These are extremely rapidly growing tumors. They're coming in at stage four. And it's whether it's young women with breast cancer, women in their 20s, something we've never seen before, young women with, men and women with colon cancer in their 20s and 30s. "Again, we've never seen—" Callender: "Two- year-olds, I've heard of two- year-olds with colon cancer—" Dr. Makis: "—we've never seen this before. That's the incredible part. And they're not responding to conventional treatments. So, they're not responding to chemo, they're not responding to radiation therapy, immunotherapy, or if they do response, they have a very, very short response time or remission time. And then the cancer comes roaring back. "And in a lot of these tragic cases, the patient dies within six months. This is another one of the features of turbo cancer is the prognosis is extremely poor if you go the conventional route. So you need something else. Now when you're using antiparasitics, for cancer, the dose is higher than the dose you would use to treat parasites or to treat Covid. So I give just a rule of thumb for ivermectin, for example, it's about five times the dose that you would need for cancer, about 5 to 10 times the dose than if you were just treating parasites or viruses. "And to go into the— why does it work? Why do these antiparasitics work?" Callender: "Cancer's a parasite?" Dr. Makis: "Well, that's one possibility. But there's more to it than that because, out of the 400 papers that have been published, a lot of those researchers look at the mechanisms. They are trying to identify the mechanisms of how ivermectin is treating these cancers. "And you've got, for example, there was one study published a few years ago, Mexican researchers, again, you're not going to see this done in the United States, Mexico. Mexican researchers took 28 different cancer cell lines, applied ivermectin to them, and all of them responded. Now to various degrees, you had breast cancer and ovarian cancer actually responding the most to ivermectin. You had the most cancer cell killing when they were exposed to ivermectin. "But when they look at the mechanisms, they've identified a number of interesting things. For example, ivermectin shuts down and kills cancer stem cells. Now, this is important because cancer stem cells are the reason chemotherapy doesn't work. When you have stage four pancreatic cancer, stage four ovarian cancer, and you go to your oncologist, they will tell you, we will give you chemo, but we can't cure you. It's palliative chemo. It'll buy you an extra six months, an extra 12 months of life. "The reason why they say that is why the chemo is palliative, not curative. It's is because chemo cannot kill cancer stem cells, which are not rapidly dividing. Chemo will kill everything that's rapidly dividing, but cancer stem cells are not rapidly dividing. And so the chemo will kill the rapidly dividing tumor cells, and it'll leave the cancer stem cells alone, while the cancer stem cells will start rapidly dividing a year later, two years later, they're going to spread to other parts of the body. Suddenly you've got recurrence, you've got metastases. Ivermectin will shut down and kill cancer stem cells. "So imagine you, added to your chemo regimen, and now you've essentially turned what's palliative chemo or a palliative situation to potentially a curative situation. And I really do believe I've come to the point, having helped over 7,000 cancer patients in the last year, I've come to the point where I could confidently say that stage 4 pancreatic cancer is curable, stage 4 ovarian cancer is curable, stage 4 colon cancer, lung cancer. These cancers are curable. I think if you add repurposed drugs, you add antiparasitics, you can turn these into curable situations. "Now, of course, we have to prove that. We have to do the research, do the publications. But in the meantime, I say stage 4 cancer patients don't have 10 years to wait for mainstream oncology or mainstream medicine to catch up with what we're seeing already clinically, in practice."

Sense Receptor

96,616 次观看 • 9 个月前

🚨 WHY ARE THERE OVER 400 PUBLISHED PAPERS ON IVERMECTIN AND CANCER? Because researchers discovered something unexpected. Ivermectin doesn't just target parasites. According to preclinical research, it appears to interact with cancer cells through multiple biological pathways. One of the most discussed? 📌 Cancer Stem Cells These are the cells believed to survive treatment, remain dormant for years, and potentially contribute to recurrence and spread. According to Dr. William Makis: 💊 Chemotherapy primarily targets rapidly dividing cancer cells. 💊 Ivermectin has been studied for its potential effects on cancer stem cells. That's why some researchers believe the combination deserves attention. But that's only part of the story. Researchers have also investigated ivermectin's potential ability to: ✅ Target cancer stem cells ✅ Influence tumor signaling pathways ✅ Alter cancer cell behavior ✅ Reverse chemotherapy resistance One of the most fascinating findings involves chemotherapy resistance. Over time, some cancer cells develop the ability to push chemotherapy drugs back out of the cell. Researchers have reported that ivermectin may interfere with these resistance mechanisms, potentially making cancer cells susceptible again. And then there's Fenbendazole and Mebendazole. While Ivermectin is being studied for one set of mechanisms, Fenbendazole and Mebendazole appear to work differently. Researchers have investigated their potential ability to: 📌 Block glucose transporters on cancer cells 📌 Reduce the cell's ability to use glucose as fuel 📌 Interfere with pathways associated with tumor growth Think about that. Different compounds. Different mechanisms. The same goal. That's why scientists continue publishing study after study. Not because these compounds are a fad. Because researchers keep uncovering new biological pathways worth investigating. And that's why the conversation around Ivermectin, Fenbendazole, and Mebendazole continues to grow. 💊 If you’re looking into these drugs, check out Ivermectin, Fenbendazole, and Mebendazole from RXMEDS.STORE. #Ivermectin #Fenbendazole #Mebendazole #CancerResearch #CancerStemCells #RepurposedDrugs #CancerBiology #RxMeds
3:32

🚨 WHY ARE THERE OVER 400 PUBLISHED PAPERS ON IVERMECTIN AND CANCER? Because researchers discovered something unexpected. Ivermectin doesn't just target parasites. According to preclinical research, it appears to interact with cancer cells through multiple biological pathways. One of the most discussed? 📌 Cancer Stem Cells These are the cells believed to survive treatment, remain dormant for years, and potentially contribute to recurrence and spread. According to Dr. William Makis: 💊 Chemotherapy primarily targets rapidly dividing cancer cells. 💊 Ivermectin has been studied for its potential effects on cancer stem cells. That's why some researchers believe the combination deserves attention. But that's only part of the story. Researchers have also investigated ivermectin's potential ability to: ✅ Target cancer stem cells ✅ Influence tumor signaling pathways ✅ Alter cancer cell behavior ✅ Reverse chemotherapy resistance One of the most fascinating findings involves chemotherapy resistance. Over time, some cancer cells develop the ability to push chemotherapy drugs back out of the cell. Researchers have reported that ivermectin may interfere with these resistance mechanisms, potentially making cancer cells susceptible again. And then there's Fenbendazole and Mebendazole. While Ivermectin is being studied for one set of mechanisms, Fenbendazole and Mebendazole appear to work differently. Researchers have investigated their potential ability to: 📌 Block glucose transporters on cancer cells 📌 Reduce the cell's ability to use glucose as fuel 📌 Interfere with pathways associated with tumor growth Think about that. Different compounds. Different mechanisms. The same goal. That's why scientists continue publishing study after study. Not because these compounds are a fad. Because researchers keep uncovering new biological pathways worth investigating. And that's why the conversation around Ivermectin, Fenbendazole, and Mebendazole continues to grow. 💊 If you’re looking into these drugs, check out Ivermectin, Fenbendazole, and Mebendazole from RXMEDS.STORE. #Ivermectin #Fenbendazole #Mebendazole #CancerResearch #CancerStemCells #RepurposedDrugs #CancerBiology #RxMeds

RXMEDS.STORE

16,612 次观看 • 2 个月前

Can Fenbendazole Cure Cancer? According to a case series published in an oncology journal, the answer could be a resounding yes. The case report highlights three cancer patients who were in pretty bad shape. But after taking fenbendazole, they all experienced a complete remission. What Is Fenbendazole, and How Does it Work? Fenbendazole (FBZ) is a medicine originally designed to treat worms and parasites in animals. Its sister drugs, Mebendazole and Albendazole, have had remarkable success treating similar ailments in humans with few side effects. Recently, anecdotal reports have praised fenbendazole as a potentially miraculous anti-cancer drug. It works by destabilizing microtubules, the structures that help cancer cells divide and grow. By disrupting this process, fenbendazole effectively halts cancer cell division and slows or stops tumor growth. Miraculous Recoveries After Taking Fenbendazole Case series #1 features a 63-year-old man with advanced kidney cancer (clear cell renal carcinoma) who experienced tumor recurrence and severe side effects from multiple cancer therapies, including surgery and two different medications. With no effective options left, he turned to fenbendazole (FBZ), taking 1 gram three times a week at a friend’s suggestion. Over the next 10 months, his tumors—including those in his pancreas and spine—showed near-complete resolution on imaging. Remarkably, he experienced no side effects from FBZ, and follow-up scans have shown no signs of recurrence. Case series #2 follows a 72-year-old man with metastatic urethral cancer that had spread to his lungs, lymph nodes, and brain. Despite undergoing multiple rounds of chemotherapy and radiation, one lymph node continued to grow, resisting all treatments. Seeking alternatives, he decided to try fenbendazole (FBZ), taking 1 gram three times a week, along with vitamin E, curcumin, and CBD oil, while postponing further conventional therapies. Over the next nine months, imaging revealed a dramatic response, with the lymph node shrinking significantly until it completely resolved. Remarkably, he reported no side effects during this period. Case series #3 focuses on a 63-year-old woman diagnosed with a large, invasive bladder tumor. Facing a challenging prognosis, she underwent chemotherapy while also taking fenbendazole (FBZ) at 1 gram three times a week. After completing six cycles of treatment, follow-up scans showed a complete resolution of the tumor, with only minimal thickening remaining in the bladder wall. Confident in her recovery, she chose to decline further surgery and remains disease-free under regular surveillance. The abstract concluded, “FBZ appears to be a potentially safe and effective antineoplastic agent that can be repurposed for human use in treating genitourinary malignancies.” Reflecting on these remarkable case reports, Dr. John Campbell (John Campbell) urged drug regulators to “start looking at this as a matter of some urgency because people are dying from cancer now.” “So if something is safe and effective, surely it can be accredited for human use by our national authorizing agencies pretty quickly if they want to,” Dr. Campbell added with a hint of sarcasm. Of course, the key words here are “if they want to.” “Three patients, basically… cured of their cancers. Read the paper for yourself. That’s what they seem to be saying to me.”
3:34

Can Fenbendazole Cure Cancer? According to a case series published in an oncology journal, the answer could be a resounding yes. The case report highlights three cancer patients who were in pretty bad shape. But after taking fenbendazole, they all experienced a complete remission. What Is Fenbendazole, and How Does it Work? Fenbendazole (FBZ) is a medicine originally designed to treat worms and parasites in animals. Its sister drugs, Mebendazole and Albendazole, have had remarkable success treating similar ailments in humans with few side effects. Recently, anecdotal reports have praised fenbendazole as a potentially miraculous anti-cancer drug. It works by destabilizing microtubules, the structures that help cancer cells divide and grow. By disrupting this process, fenbendazole effectively halts cancer cell division and slows or stops tumor growth. Miraculous Recoveries After Taking Fenbendazole Case series #1 features a 63-year-old man with advanced kidney cancer (clear cell renal carcinoma) who experienced tumor recurrence and severe side effects from multiple cancer therapies, including surgery and two different medications. With no effective options left, he turned to fenbendazole (FBZ), taking 1 gram three times a week at a friend’s suggestion. Over the next 10 months, his tumors—including those in his pancreas and spine—showed near-complete resolution on imaging. Remarkably, he experienced no side effects from FBZ, and follow-up scans have shown no signs of recurrence. Case series #2 follows a 72-year-old man with metastatic urethral cancer that had spread to his lungs, lymph nodes, and brain. Despite undergoing multiple rounds of chemotherapy and radiation, one lymph node continued to grow, resisting all treatments. Seeking alternatives, he decided to try fenbendazole (FBZ), taking 1 gram three times a week, along with vitamin E, curcumin, and CBD oil, while postponing further conventional therapies. Over the next nine months, imaging revealed a dramatic response, with the lymph node shrinking significantly until it completely resolved. Remarkably, he reported no side effects during this period. Case series #3 focuses on a 63-year-old woman diagnosed with a large, invasive bladder tumor. Facing a challenging prognosis, she underwent chemotherapy while also taking fenbendazole (FBZ) at 1 gram three times a week. After completing six cycles of treatment, follow-up scans showed a complete resolution of the tumor, with only minimal thickening remaining in the bladder wall. Confident in her recovery, she chose to decline further surgery and remains disease-free under regular surveillance. The abstract concluded, “FBZ appears to be a potentially safe and effective antineoplastic agent that can be repurposed for human use in treating genitourinary malignancies.” Reflecting on these remarkable case reports, Dr. John Campbell (John Campbell) urged drug regulators to “start looking at this as a matter of some urgency because people are dying from cancer now.” “So if something is safe and effective, surely it can be accredited for human use by our national authorizing agencies pretty quickly if they want to,” Dr. Campbell added with a hint of sarcasm. Of course, the key words here are “if they want to.” “Three patients, basically… cured of their cancers. Read the paper for yourself. That’s what they seem to be saying to me.”

The Vigilant Fox 🦊

1,478,253 次观看 • 1 年前